Sipavibart Neutralizing Predictions Exceed Comparator Thresholds in Early Phase COVID-19 Clinical Trials
Phase 1 and phase 2 trials demonstrate the safety, pharmacokinetics, and noninferior predicted neutralizing activity of sipavibart against SARS-CoV-2 BA.2.86 ...

